Cytomx Therapeutics

Cytomx Therapeutics company information, Employees & Contact Information

CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development. Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes and holding each other to the highest possible standards. CytomX embraces diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves, feel involved, respected and connected. We at CytomX believe that we benefit from each other’s ideas and experiences. We accept our differences and learn from one another, improve together, and embrace change to achieve our corporate and individual objectives. This belief applies to how we work together at CytomX, how we work with others outside CytomX, how we represent CytomX in our communities, and how we endeavor to bring our scientific innovations to a diverse patient population. CytomX acknowledges the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. CytomX is an equal opportunity employer and does not discriminate against any individual or potential candidate because of race, color, religion, sex, national origin, sexual preference or any other legally protected category. CytomX is located in South San Francisco, California, the birthplace of biotechnology. Learn more about us and how we are advancing science to treat cancer differently at www.cytomX.com.

Company Details

Employees
110
Address
151 Oyster Point Blvd, South San Francisco,ca 94080,united States
Phone
6503510353
Industry
Biotechnology
Website
cytomx.com
HQ
South San Francisco, CA
Looking for a particular Cytomx Therapeutics employee's phone or email?

Cytomx Therapeutics Questions

News

CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer - Yahoo Finance

CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer Yahoo Finance

CytomX Therapeutics Appoints Rachael Lester as Senior Vice President, Chief Business Officer - Quiver Quantitative

CytomX Therapeutics Appoints Rachael Lester as Senior Vice President, Chief Business Officer Quiver Quantitative

CytomX (Nasdaq: CTMX) appoints Rachael Lester CBO to lead strategy and partnerships - Stock Titan

CytomX (Nasdaq: CTMX) appoints Rachael Lester CBO to lead strategy and partnerships Stock Titan

CytomX Therapeutics Reports Promising Interim Phase 1 Data for CX-2051 in Advanced Colorectal Cancer with Plans for Phase 2 Study Initiation - Nasdaq

CytomX Therapeutics Reports Promising Interim Phase 1 Data for CX-2051 in Advanced Colorectal Cancer with Plans for Phase 2 Study Initiation Nasdaq

CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 - Yahoo Finance

CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 Yahoo Finance

CytomX Therapeutics Sets Q2 Earnings Date: Biotech Leader to Update on Masked Biologics Progress - Stock Titan

CytomX Therapeutics Sets Q2 Earnings Date: Biotech Leader to Update on Masked Biologics Progress Stock Titan

CytomX Therapeutics Doses First Patient in Phase 1 Study of CX-801 Combined with KEYTRUDA® for Metastatic Melanoma - Quiver Quantitative

CytomX Therapeutics Doses First Patient in Phase 1 Study of CX-801 Combined with KEYTRUDA® for Metastatic Melanoma Quiver Quantitative

CytomX Therapeutics to Present at Upcoming September Investor Conferences - Yahoo Finance

CytomX Therapeutics to Present at Upcoming September Investor Conferences Yahoo Finance

CytomX Earnings: Breakthrough Colorectal Cancer Drug Shows Promise as Company Raises $100M - Stock Titan

CytomX Earnings: Breakthrough Colorectal Cancer Drug Shows Promise as Company Raises $100M Stock Titan

CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study - Yahoo Finance

CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study Yahoo Finance

CytomX Therapeutics Focuses on Lead Program CX-2051 and Streamlines Operations for 2025 - Quiver Quantitative

CytomX Therapeutics Focuses on Lead Program CX-2051 and Streamlines Operations for 2025 Quiver Quantitative

CytomX Therapeutics CEO Set for Jefferies Conference: Key Biologics Updates Coming - Stock Titan

CytomX Therapeutics CEO Set for Jefferies Conference: Key Biologics Updates Coming Stock Titan

CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

CytomX Cancer Drug Trial Continues Despite Patient Death, Phase 1 Data Expected Q1 2026 - Stock Titan

CytomX Cancer Drug Trial Continues Despite Patient Death, Phase 1 Data Expected Q1 2026 Stock Titan

Biotech Leader CytomX Sets Q1 2025 Earnings Date: Key Details for Investors - Stock Titan

Biotech Leader CytomX Sets Q1 2025 Earnings Date: Key Details for Investors Stock Titan

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - Yahoo Finance

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock Yahoo Finance

CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - Stock Titan

CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update Stock Titan

CytomX Unveils Breakthrough Cancer Treatment Data with Moderna at AACR | CTMX Stock News - Stock Titan

CytomX Unveils Breakthrough Cancer Treatment Data with Moderna at AACR | CTMX Stock News Stock Titan

CytomX Therapeutics to Present at Upcoming September Investor Conferences - Stock Titan

CytomX Therapeutics to Present at Upcoming September Investor Conferences Stock Titan

CytomX has a tox wobble | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

CytomX has a tox wobble | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Do CytomX Therapeutics' (NASDAQ:CTMX) Earnings Warrant Your Attention? - Yahoo Finance

Do CytomX Therapeutics' (NASDAQ:CTMX) Earnings Warrant Your Attention? Yahoo Finance

Why CytomX Therapeutics Stock Was Skyrocketing This Week - The Motley Fool

Why CytomX Therapeutics Stock Was Skyrocketing This Week The Motley Fool

CytomX shifts towards EpCAM | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

CytomX shifts towards EpCAM | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

CytomX reports patient death from kidney injury in ADC trial - Fierce Biotech

CytomX reports patient death from kidney injury in ADC trial Fierce Biotech

Deals mask CytomX’s fundamental problem | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Deals mask CytomX’s fundamental problem | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

CytomX: A Fresh Start With New Drugs After Total Pipeline Failure (NASDAQ:CTMX) - Seeking Alpha

CytomX: A Fresh Start With New Drugs After Total Pipeline Failure (NASDAQ:CTMX) Seeking Alpha

John A. Scarlett, M.D. Retires From CytomX Therapeutics Board - citybiz

John A. Scarlett, M.D. Retires From CytomX Therapeutics Board citybiz

CytomX Therapeutics: Updated Outlook For Late 2025 (NASDAQ:CTMX) - Seeking Alpha

CytomX Therapeutics: Updated Outlook For Late 2025 (NASDAQ:CTMX) Seeking Alpha

CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P. - Stock Titan

CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P. Stock Titan

CytomX delivers a pancreatic surprise | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

CytomX delivers a pancreatic surprise | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

CytomX Reports Treatment-Related Patient Death in Phase I Colorectal Cancer Study - BioSpace

CytomX Reports Treatment-Related Patient Death in Phase I Colorectal Cancer Study BioSpace

CX-2051 Demonstrates Preliminary Activity in Heavily Pretreated Advanced Colorectal Cancer - OncLive

CX-2051 Demonstrates Preliminary Activity in Heavily Pretreated Advanced Colorectal Cancer OncLive

CTMX.O - | Stock Price & Latest News - Reuters

CTMX.O - | Stock Price & Latest News Reuters

CytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish? - Seeking Alpha

CytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish? Seeking Alpha

CytomX to Cut 40% of Staff as It Updates Pipeline Priorities - BioSpace

CytomX to Cut 40% of Staff as It Updates Pipeline Priorities BioSpace

Amgen and CytomX throw off masked T-cell engager, axing asset after assessing data, priorities - Fierce Biotech

Amgen and CytomX throw off masked T-cell engager, axing asset after assessing data, priorities Fierce Biotech

Bay Area biotech firm CytomX, once worth $1.2 billion, lays off 40% of staff - SFGATE

Bay Area biotech firm CytomX, once worth $1.2 billion, lays off 40% of staff SFGATE

Moderna signs $35 million deal with cancer drug developer CytomX - Reuters

Moderna signs $35 million deal with cancer drug developer CytomX Reuters

CytomX slashes headcount by 40% after breast cancer setback, with later-stage development bearing the brunt - Fierce Biotech

CytomX slashes headcount by 40% after breast cancer setback, with later-stage development bearing the brunt Fierce Biotech

Regeneron, CytomX Ink Potentially $2B Bispecific Immunotherapy Deal (Updated) - BioSpace

Regeneron, CytomX Ink Potentially $2B Bispecific Immunotherapy Deal (Updated) BioSpace

Targeting CD166 Represents a New Avenue of Attack for Breast Cancer - OncLive

Targeting CD166 Represents a New Avenue of Attack for Breast Cancer OncLive

CytomX Therapeutics Inc (CTMX) Stock Price, Trades & News - GuruFocus

CytomX Therapeutics Inc (CTMX) Stock Price, Trades & News GuruFocus

CTMX - Cytomx Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

CTMX - Cytomx Therapeutics Inc Latest Stock News & Market Updates Stock Titan

CTMX Stock Price and Chart — NASDAQ:CTMX - TradingView

CTMX Stock Price and Chart — NASDAQ:CTMX TradingView

FierceBiotech's 2013 Fierce 15 - Fierce Biotech

FierceBiotech's 2013 Fierce 15 Fierce Biotech

Top Cytomx Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant